LCA-2, for example, involves a loss of function in both copies of a gene known as RPE65.
Although results are unlikely to be published for some time, the medical team hope that the insertion of a correct copy of the RPE65 gene will allow patients to recover, or in the very least, retain a degree of sight.
RPE65 |